Healthcare
Healthcare Investment Banking Group
Finding financial solutions across every sector of the healthcare ecosystem.
A full-service healthcare investment banking practice offering a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise.
Stifel’s Global Healthcare Investment Banking Group is comprised of 47 professionals covering all segments of the healthcare industry. The team, located in New York, San Francisco, London, Toronto, and Montreal, has substantial experience in assisting companies with all types of financing and M&A assignments. The Global Healthcare Group is dedicated to building long-term relationships with its clients through senior level attention. Since the formation of the Global Healthcare Group in Q4 2010, the team have helped raise over $79.1 billion for over 225 healthcare companies in over 440 transactions. Over the same period, members of the Global Healthcare Group have advised on over 105 announced M&A transactions, including over 30 cross-border assignments.
Our team provides clients with strategic advisory and capital-raising services designed to support growth companies and their investors during all stages of their development. We offer equity and debt capital markets services, including book running leading IPOs, follow-ons, and convertible note issuances. The Global Healthcare Group is supported by M&A advisory with extensive cross-border expertise, access to private capital markets through SPACs and 144A solutions, as well as activism defense and restructuring.
Areas of Expertise
Biopharma
The biopharma sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all stages of development and therapeutic areas. Stifel’s Biopharma team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the biopharma landscape, and our extensive relationships and transaction experience.
Healthcare Services
The healthcare services landscape is constantly shifting, driven by changes in regulations, reimbursement, and advancements in technology. Stifel’s Healthcare Services Team works to stay abreast of these changes and is ideally positioned to serve the needs of our clients in all types of financing and M&A assignments via relationships, recent mandates, and years of thought leadership across a broad range of healthcare sub-sectors including Alternate Site, Behavioral Health, Payor Services, Pharma Services, and Physician Groups.
HealthTech
Technologies are rapidly advancing the automation of workflows across the healthcare ecosystem, the development and efficacy of treatments, and the way in which care is provided in-person and remotely. Stifel’s Healthcare Technology team brings a wealth of M&A and financing experience advising companies delivering software, digital health, data-driven, and technology-enabled solutions to providers, payors, pharmaceutical companies, and patients.
Medtech
The Medtech sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all Medtech subsectors. Stifel’s Medtech team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the Medtech landscape, and our extensive relationships and transaction experience.
Tools & Diagnostics
The life science tools & diagnostics sector is transforming at amazing speeds. Enabled by a broad array of new technologies, our ability to better understand all facets of the human genome has improved exponentially; all the while being done at greater efficiency and dramatically reduced costs. This widening knowledge set is enabling faster and more productive drug discovery, disease diagnosis and AI-enabled prognostic clinical capabilities. Stifel’s Life Science Tools & Diagnostics team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our broad domain expertise, deep understanding of the competitive landscape, and our extensive relationships and transaction experience.
Read our June 2024 Oncology Market Report, a summary of recent deal activity, and new developments from the American Society of Clinical Oncology conference.
Learn MoreNotable Transactions
![Nabriva Therapeutics_Meithal MA](https://stifelinstitutional.com/wp-content/uploads/2024/07/Nabriva_Meitheal_Logo.png)
Advisor to Seller
Biopharma | July 2024![Onward Medical SCF](https://stifelinstitutional.com/wp-content/uploads/2024/07/OnwardMedical_logo.png)
€ 52,500,000
Exclusive Debt Advisor
Healthcare | June 2024![Rapport Therapeutics IPO](https://stifelinstitutional.com/wp-content/uploads/2024/06/RapportTherpeutics_Logo.png)
$ 174,400,000
Joint Bookrunner
Biopharma | June 2024![Celcuity Registered Direct](https://stifelinstitutional.com/wp-content/uploads/2024/06/Celcuity_logo.png)
$ 60,000,000
Joint Bookrunner
Biopharma | May 2024![Dyne Follow-on](https://stifelinstitutional.com/wp-content/uploads/2021/02/Dyne-Therapeutics_logo.png)
$ 374,325,000
Joint Bookrunner
Biopharma | May 2024![Abeona Registered Direct](https://stifelinstitutional.com/wp-content/uploads/2024/06/Abeona_Logo.png)
$ 75,000,000
Sole Bookrunner
Biopharma | May 2024![Sientra Agg Indebtedness 0424](https://stifelinstitutional.com/wp-content/uploads/2024/04/Sientra_Logo.png)
$ 94,300,000
Advisor to Sientra
Medtech | April 2024![Sientra Tiger Nuance MA 0424](https://stifelinstitutional.com/wp-content/uploads/2024/04/Sientra_Tiger_Nuance_Logo.png)
$ 121,600,000
Advisor to Seller
Medtech | April 2024![Cullinan Therapeutics](https://stifelinstitutional.com/wp-content/uploads/2024/04/Cullinan_Logo.png)
$ 280,000,000
Joint Placement Agent
Biopharma | April 2024![Nurix Therapeutics](https://stifelinstitutional.com/wp-content/uploads/2021/05/Nurix_Logo.png)
$ 201,250,000
Joint Bookrunner
Biopharma | April 2024![Contineum Therapeutics IPO](https://stifelinstitutional.com/wp-content/uploads/2024/04/Contineum.png)
$ 110,000,000
Joint Bookrunner
Biopharma | April 2024![Upsher-Smith_Bora Pharmaceuticals](https://stifelinstitutional.com/wp-content/uploads/2024/04/Upshersmith_Borapharmaceuticals_Logo.png)
Advisor to Seller
Biopharma | April 2024![NervGen Pharma Corp Follow-on](https://stifelinstitutional.com/wp-content/uploads/2024/04/NervGenPharma.png)
C$ 23,011,788
Joint Bookrunner
Life Sciences & Healthcare | March 2024![Avalo_AlmataBio_MA_March](https://stifelinstitutional.com/wp-content/uploads/2024/04/Avalo_AlmataBio_Logo-1.png)
Financial Advisor
Biopharma | March 2024![Nkarta Registered Direct](https://stifelinstitutional.com/wp-content/uploads/2024/04/nkarta_logo-1.png)
$ 240,100,310
Joint Bookrunner
Biopharma | March 2024![Geron Registered Direct](https://stifelinstitutional.com/wp-content/uploads/2022/04/Geron_Logo.png)
$ 150,000,000
Joint Bookrunner
Biopharma | March 2024![Spyre Therapeutics PIPE](https://stifelinstitutional.com/wp-content/uploads/2023/12/SpyreTherapeutics_Logo.png)
$ 180,000,000
Joint Placement Agent
Biopharma | March 2024![Apogee Therapeutics](https://stifelinstitutional.com/wp-content/uploads/2023/07/Apogee_Logo.png)
$ 482,999,902
Joint Bookrunner
Biopharma | March 2024![Regenxbio Follow-on](https://stifelinstitutional.com/wp-content/uploads/2024/03/Regenxbio_Logo.png)
$ 140,000,000
Joint Bookrunner
Biopharma | March 2024![South Coast Retina_ Retina Consultants of America MA](https://stifelinstitutional.com/wp-content/uploads/2024/03/SouthCoastRetina_RetinaConsultants_Logo.png)
Advisor to Seller
Healthcare Services | March 2024![Avacta](https://stifelinstitutional.com/wp-content/uploads/2022/11/Avacta_logo.png)
£ 31,000,000
Joint Bookrunner, Joint Corporate Broker, NOMAD
Healthcare | March 2024![Viking Follow-on](https://stifelinstitutional.com/wp-content/uploads/2024/03/Viking_Logo.png)
$ 632,540,250
Joint Bookrunner
Biopharma | February 2024![Dario Health](https://stifelinstitutional.com/wp-content/uploads/2024/02/Dario_Twill_Logo.png)
$ 34,400,000
Advisor to Buyer
HealthTech | February 2024![Numinus Follow-on](https://stifelinstitutional.com/wp-content/uploads/2024/02/Numinus_Logo.png)
C$ 6,000,000
![KalVista FO](https://stifelinstitutional.com/wp-content/uploads/2021/03/KalVista_logo.png)
$ 160,125,000
Joint Bookrunner
Biopharma | February 2024![Dyne Therapeutics](https://stifelinstitutional.com/wp-content/uploads/2021/02/Dyne-Therapeutics_logo.png)
$ 345,144,000
Joint Bookrunner
Biopharma | January 2024![Syndax CMO](https://stifelinstitutional.com/wp-content/uploads/2023/12/Syndax_Logo.png)
$ 230,000,000
Joint Bookrunner
Biopharma | December 2023![Cibus Registered Direct](https://stifelinstitutional.com/wp-content/uploads/2023/12/Cibus_Logo.png)
$ 20,300,000
Left Bookrunner
HealthTech | December 2023![Spyre PIPE](https://stifelinstitutional.com/wp-content/uploads/2023/12/SpyreTherapeutics_Logo.png)
$ 180,000,000
Joint Placement Agent
Biopharma | December 2023![Vanda_Johnson & Johnson MA](https://stifelinstitutional.com/wp-content/uploads/2023/12/Vanda_Ponvory_Johnson_Logo.png)
$ 100,000,000
Advisor to Buyer
Biopharma | December 2023![Xenon](https://stifelinstitutional.com/wp-content/uploads/2023/12/Xenon_Logo.png)
$ 300,000,000
Joint Bookrunner
Biopharma | November 2023![M8 Pharmaceuticals_Acino](https://stifelinstitutional.com/wp-content/uploads/2023/12/M8_MGP_Acino_ADQ_Logo.png)
Advisor to Seller
Biopharma | November 2023![Teijin_Ascendis](https://stifelinstitutional.com/wp-content/uploads/2023/12/Teijin_Ascendis_Logo.png)
$ 245,000,000+
Advisor to Licensee
Biopharma | November 2023![Medstrat_Zimmer Biomet MA](https://stifelinstitutional.com/wp-content/uploads/2023/12/Medstrat_ZimmerBiomet_Logo.png)
Advisor to Seller
HealthTech | November 2023![Lexeo IPO](https://stifelinstitutional.com/wp-content/uploads/2023/11/LexeoTherapeutics_Logo.png)
$ 111,536,216
Joint Bookrunner
Biopharma | November 2023![Alphatec CMO](https://stifelinstitutional.com/wp-content/uploads/2023/11/Alphatec_Logo.png)
$ 150,150,000
Joint Bookrunner
Medtech | October 2023![Cerevel CMO](https://stifelinstitutional.com/wp-content/uploads/2021/08/Cerevel_logo.png)
$ 517,500,000
Joint Bookrunner
Biopharma | October 2023![Biocorp](https://stifelinstitutional.com/wp-content/uploads/2023/10/Biocorp_NovoNordisk_Logo.png)
€ 154,430,010
Advisor to Seller
Medtech | October 2023![Vistagen Registered Direct](https://stifelinstitutional.com/wp-content/uploads/2023/10/Vistagen_Logo.png)
$ 100,000,000
Joint Bookrunner
Biopharma | October 2023![Immunome_Morphimmune MA](https://stifelinstitutional.com/wp-content/uploads/2023/10/Immunome_Morphimmune_Logo.png)
$ 90,833,010
Advisor to Buyer
Biopharma | October 2023![Infirst_Carlin MA](https://stifelinstitutional.com/wp-content/uploads/2023/10/Infirst_Carlin_Logo.png)
Advisor to Seller
Healthcare | September 2023![Hillevax CMO](https://stifelinstitutional.com/wp-content/uploads/2023/09/HilleVax_logo.png)
$ 115,000,000
Joint Bookrunner
Biopharma | September 2023![Neumora IPO](https://stifelinstitutional.com/wp-content/uploads/2023/09/Neumora_Logo.png)
$ 250,070,000
Joint Bookrunner
Biopharma | September 2023![Acumen FO](https://stifelinstitutional.com/wp-content/uploads/2021/08/Acumen_logo.png)
$ 130,000,000
Joint Bookrunner
Biopharma | July 2023![Apogee IPO](https://stifelinstitutional.com/wp-content/uploads/2023/07/Apogee_Logo.png)
$ 345,057,500
Joint Bookrunner
Biopharma | July 2023![Kooth Follow-on](https://stifelinstitutional.com/wp-content/uploads/2023/07/Kooth_Logo.png)
£ 10,000,000
Joint Bookrunner
Healthcare | July 2023![IGM Biosciences](https://stifelinstitutional.com/wp-content/uploads/2023/06/IGM_2023.png)
$ 120,000,000
Joint Bookrunner
Biopharma | June 2023![Disc Medicine Follow-on](https://stifelinstitutional.com/wp-content/uploads/2023/06/DiscMedicine_Logo.png)
$ 137,200,000
Joint Bookrunner
Biopharma | June 2023![Tricida Chapter 11](https://stifelinstitutional.com/wp-content/uploads/2023/07/Tricida_Logo.png)
$ 200,000,000
Investment Banker for Tricida
Biopharma | June 2023![30 Technology_Convatec MA](https://stifelinstitutional.com/wp-content/uploads/2023/05/30technology_Convatec_Logo.png)
£ 176,000,000
Financial Advisor
Medtech | April 2023![Karuna Follow-on](https://stifelinstitutional.com/wp-content/uploads/2021/05/KarunaTherapeutic_Logos.png)
$ 460,000,000
Joint Bookrunner
Biopharma | March 2023![Mineralys IPO](https://stifelinstitutional.com/wp-content/uploads/2023/02/MineralysTherapeutics_Logo.png)
$ 220,800,000
Joint Bookrunner
Biopharma | February 2023![Renalytix PIPE](https://stifelinstitutional.com/wp-content/uploads/2022/04/renalytix_logo.png)
$ 20,300,000
Sole Placement Agent and Nomad
Healthcare | February 2023![Treace Medical CMO](https://stifelinstitutional.com/wp-content/uploads/2023/02/Treace_Logo.png)
$ 100,000,000
Joint Bookrunner
Medtech | February 2023![Geron Follow-on](https://stifelinstitutional.com/wp-content/uploads/2022/04/Geron_Logo.png)
$ 227,843,965
Joint Bookrunner
Biopharma | January 2023![Bioassay_ReactionBiology](https://stifelinstitutional.com/wp-content/uploads/2022/12/Bioassay_ReactionBiology_Logo.png)
Advisor to Seller
Healthcare | December 2022![Cutera](https://stifelinstitutional.com/wp-content/uploads/2021/05/Cutera_Logo.png)
$ 120,000,000
Left Bookrunner
Medtech | December 2022![VOR Registered Direct](https://stifelinstitutional.com/wp-content/uploads/2021/03/VorBiopharma_logo.png)
$ 115,799,748
Joint Bookrunner & Joint Placement Agent
Biopharma | December 2022![X4 Pharmaceuticals](https://stifelinstitutional.com/wp-content/uploads/2021/05/X4_Logo.png)
$ 65,010,000
Joint Bookrunner
Biopharma | December 2022![Unimed_ZCG](https://stifelinstitutional.com/wp-content/uploads/2022/12/Unimed_Comvest_ZCG.png)
Advisor to Seller
Maritime Services, Healthcare Services | December 2022![Iveric Bio CMO](https://stifelinstitutional.com/wp-content/uploads/2021/08/Ivericbio_logo.png)
$ 300,375,000
Joint Bookrunner
Biopharma | December 2022![Purigen Biosystems_Bionano](https://stifelinstitutional.com/wp-content/uploads/2022/12/Purigen_Bionano.png)
$ 64,000,000
Advisor to Seller
Tools & Diagnostics | November 2022![OmniAb_Avista MA](https://stifelinstitutional.com/wp-content/uploads/2022/11/OmniAb_Avista_Logo.png)
$ 850,000,000
Financial and Capital Markets Advisor
Biopharma | November 2022![Silkroad Follow-on](https://stifelinstitutional.com/wp-content/uploads/2022/10/Silkroad_Logo.png)
$ 115,000,000
Joint Bookrunner
Medtech | October 2022![Avacta Group Convertible Bond FO](https://stifelinstitutional.com/wp-content/uploads/2022/11/Avacta_logo.png)
£ 64,000,000
Sole Bookrunner, Sole Placement Agent, Sole Broker and Nomad
Healthcare Services | October 2022![Trevi CMO](https://stifelinstitutional.com/wp-content/uploads/2022/10/TreviTherapeutics_logo.png)
$ 58,079,577
Joint Bookrunner
Biopharma | September 2022![Rhythm CMO](https://stifelinstitutional.com/wp-content/uploads/2021/03/RhythmPharmaceuticals_logo.png)
$ 124,800,000
Joint Bookrunner
Biopharma | September 2022![Medpharmex_Dechra MA](https://stifelinstitutional.com/wp-content/uploads/2022/09/MedPharmex_DWHP_Dechra_Logo.png)
$ 260,000,000
Advisor to Seller
Healthcare Services | August 2022![Fulcrum Therapeutics CMO](https://stifelinstitutional.com/wp-content/uploads/2022/08/FulcrumTherapeutics_logo.png)
$ 84,249,986
Joint Bookrunner
Biopharma | August 2022![Orthopediatrics CMO](https://stifelinstitutional.com/wp-content/uploads/2022/08/Orthopediatrics_Logo.png)
$ 143,893,750
Joint Bookrunner
Medtech | August 2022![Karuna Follow-on](https://stifelinstitutional.com/wp-content/uploads/2021/05/KarunaTherapeutic_Logos.png)
$ 862,500,000
Lead Manager
Biopharma | August 2022![Invacare SSTL](https://stifelinstitutional.com/wp-content/uploads/2022/08/Invacare_logo.png)
$ 104,500,000
Sole Placement Agent
Medtech | July 2022![Invacare CN](https://stifelinstitutional.com/wp-content/uploads/2022/08/Invacare_logo.png)
$ 55,300,000
Sole Bookrunner
Medtech | July 2022![Natus_ArchiMed MA](https://stifelinstitutional.com/wp-content/uploads/2022/08/Natus_ArchMed_Logo.png)
$ 1,200,000,000
Advisor to Seller
Medtech | July 2022![Xenon CMO](https://stifelinstitutional.com/wp-content/uploads/2021/03/Xenon_logo.png)
$ 250,000,000
Joint Bookrunner
HealthTech | June 2022![Well Health Follow-on](https://stifelinstitutional.com/wp-content/uploads/2021/11/Wellhealth_logo.png)
C$ 34,511,565
Joint Bookrunner
HealthTech | May 2022![Redex Pharma Follow-on](https://stifelinstitutional.com/wp-content/uploads/2022/05/Redex.png)
£ 34,261,864
Joint Bookrunner
Biopharma | May 2022![PepGen](https://stifelinstitutional.com/wp-content/uploads/2022/05/PepGen_Logo.png)
$ 108,000,000
Joint Bookrunner
Biopharma | May 2022![Integra_Anthem M&A](https://stifelinstitutional.com/wp-content/uploads/2022/05/Integra_Athem_Logo.png)
Advisor to Seller
Healthcare Services | May 2022![HilleVax IPO](https://stifelinstitutional.com/wp-content/uploads/2022/04/HilleVax-scaled.jpg)
$ 200,000,000
Joint Bookrunner
Biopharma | April 2022![Nkarta CMO](https://stifelinstitutional.com/wp-content/uploads/2022/04/Nkarta.jpg)
$ 230,000,000
Joint Bookrunner
Biopharma | April 2022![Hyloris Follow-on](https://stifelinstitutional.com/wp-content/uploads/2022/04/Hyloris.png)
€ 15,000,000
Joint Global Coordinator and Joint Bookrunner
Healthcare | April 2022![Renalytix](https://stifelinstitutional.com/wp-content/uploads/2022/04/renalytix_logo.png)
$ 30,000,000
Sole Financial Advisor and Sole Placement Agent
Medtech | March 2022![IGM Follow-on 03/22](https://stifelinstitutional.com/wp-content/uploads/2021/02/igm-bio_logo.png)
$ 230,000,000
Joint Bookrunner
Biopharma | March 2022![Geron CMO 03/22](https://stifelinstitutional.com/wp-content/uploads/2022/04/Geron_Logo.png)
$ 75,000,000
Left Bookrunner
Biopharma | March 2022![Dario Health Registered Direct](https://stifelinstitutional.com/wp-content/uploads/2021/02/DarioHealth-Group_logo.png)
$ 40,000,000
Financial Advisor
HealthTech | March 2022![Athenahealth Senior Notes](https://stifelinstitutional.com/wp-content/uploads/2022/03/Athenahealth_BainCapital_Hellman_logo.png)
$ 2,350,000,000
Joint Bookrunner
HealthTech | February 2022![Zymeworks CMO](https://stifelinstitutional.com/wp-content/uploads/2022/01/Zymeworks_Logo.png)
$ 100,000,000
Joint Bookrunner
Biopharma | January 2022![Vigil IPO](https://stifelinstitutional.com/wp-content/uploads/2022/01/VigilNeuro_Logo.png)
$ 98,000,000
Joint Bookrunner
Biopharma | January 2022![Mississippi_Retina M&A](https://stifelinstitutional.com/wp-content/uploads/2021/12/Mississippi_Retina_Logo.png)
Advisor to Seller
Healthcare Services | December 2021![MEI Pharma Follow-on](https://stifelinstitutional.com/wp-content/uploads/2021/12/MEIPharma_Logo.png)
$ 52,325,000
Joint Bookrunner
Biopharma | December 2021![Wellhealth](https://stifelinstitutional.com/wp-content/uploads/2021/11/Wellhealth_logo.png)
C$ 65,000,000
Co-Lead Manager
HealthTech | November 2021![ALSP Orchid SPAC IPO](https://stifelinstitutional.com/wp-content/uploads/2021/11/ALSPOrching_Logo.png)
$ 172,500,000
Left Bookrunner
Biopharma | November 2021![ViewRay CMO](https://stifelinstitutional.com/wp-content/uploads/2021/11/ViewRay_Logo.png)
$ 80,500,000
Joint Bookrunner
Medtech | November 2021![Prilenia Private Placement](https://stifelinstitutional.com/wp-content/uploads/2022/04/Prilenia_logo.png)
$ 43,000,000
Lead Placement Agent
Biopharma | November 2021![908 Devices Follow-on](https://stifelinstitutional.com/wp-content/uploads/2021/02/908-devices_logo.png)
$ 100,800,000
Joint Bookrunner
Tools & Diagnostics | November 2021![Motion_Docgo M&A](https://stifelinstitutional.com/wp-content/uploads/2021/11/Motion_Docgo_logo.png)
$ 158,000,000
Capital Markets Advisor
HealthTech | November 2021![BioCare_Vistria M&A](https://stifelinstitutional.com/wp-content/uploads/2021/11/BioCare_Vistria_Logo.png)
Advisor to Seller
Healthcare Services | November 2021![Spindletop IPO](https://stifelinstitutional.com/wp-content/uploads/2021/11/Spindletop_logo.png)
$ 230,000,000
Joint Bookrunner
Healthcare Services | November 2021![Sonendo IPO](https://stifelinstitutional.com/wp-content/uploads/2021/11/Sonendo_logo.png)
$ 93,600,000
Joint Bookrunner
Medtech | October 2021![Iveric Bio CMO](https://stifelinstitutional.com/wp-content/uploads/2021/08/Ivericbio_logo.png)
$ 150,750,000
Joint Bookrunner
Biopharma | October 2021![Ventripoint Follow-on](https://stifelinstitutional.com/wp-content/uploads/2021/10/Ventripoint_Logo.png)
C$ 7,004,400
Joint Bookrunner
Life Sciences & Healthcare | October 2021![Apollo CMO](https://stifelinstitutional.com/wp-content/uploads/2021/10/ApolloEndosurgery_logo.png)
$ 74,865,000
Joint Bookrunner
Medtech | October 2021![Xenon Follow-on Offering](https://stifelinstitutional.com/wp-content/uploads/2021/03/Xenon_logo.png)
$ 345,000,000
Joint Bookrunner
Medtech | October 2021![Zomedica_PulseVet M&A](https://stifelinstitutional.com/wp-content/uploads/2021/10/Zomedica_Pulsevet_Branford_Logo.png)
$ 70,900,000
Advisor to Buyer
Medtech | October 2021![Ekkio_LIM M&A](https://stifelinstitutional.com/wp-content/uploads/2021/10/Ekkio_LIM_Logo.png)
Advisor to Seller
Medtech | October 2021![Greenbrook Follow-on](https://stifelinstitutional.com/wp-content/uploads/2021/09/GreenbrookTM.png)
$ 13,200,000
Joint Bookrunner
Healthcare Services | September 2021![Audax M&A](https://stifelinstitutional.com/wp-content/uploads/2021/09/Audax_GCX_logo.png)
Advisor to Buyer
Medtech | September 2021![Maravai Follow-on](https://stifelinstitutional.com/wp-content/uploads/2021/09/Maravai_logo.png)
$ 1,000,000,000
Joint Bookrunner
Biopharma | September 2021![Somalogic_CM Life SPAC Merger](https://stifelinstitutional.com/wp-content/uploads/2021/09/Somalogic_CM.png)
$ 651,000,000
Capital Markets Advisor
Tools & Diagnostics | September 2021![Atlas Antibodies – Afinum – SHS M&A](https://stifelinstitutional.com/wp-content/uploads/2021/08/Atlas_Afinum_Logo.png)
Advisor to Buyer
Biopharma | August 2021![Surrozen](https://stifelinstitutional.com/wp-content/uploads/2021/08/Surrozen_logo.png)
$ 212,000,000
Capital Markets Advisor
Biopharma | August 2021![Adagio](https://stifelinstitutional.com/wp-content/uploads/2021/08/Adagio.png)
$ 355,810,000
Joint Bookrunner
Biopharma | August 2021![Rani Therapeutics IPO](https://stifelinstitutional.com/wp-content/uploads/2021/08/RaniTherapeutics_logo.png)
$ 84,333,337
Joint Bookrunner
Biopharma | July 2021![Absci IPO](https://stifelinstitutional.com/wp-content/uploads/2021/08/Absci_logo.png)
$ 230,000,000
Joint Bookrunner
Tools & Diagnostics | July 2021![BioAgri – DWHP M&A](https://stifelinstitutional.com/wp-content/uploads/2021/08/BioAgri__Birchhill_DWHP.png)
Advisor to Seller
Biopharma | July 2021![Gen inCode IPO](https://stifelinstitutional.com/wp-content/uploads/2021/08/GeninCode_logo.png)
£ 17,000,000
Sole Global Coordinator, Joint Bookrunner & Nomad
HealthTech | July 2021![Imago Biosciences IPO](https://stifelinstitutional.com/wp-content/uploads/2021/08/Imagobioscience_logo.png)
$ 174,560,000
Joint Bookrunner
Biopharma | July 2021![Rapidmicro IPO](https://stifelinstitutional.com/wp-content/uploads/2021/08/RapidMciroBiosystem_logo.png)
$ 180,132,080
Joint Bookrunner
Tools & Diagnostics | July 2021![LeMaitre CMO](https://stifelinstitutional.com/wp-content/uploads/2021/08/LeMaitre_logo.png)
$ 62,675,000
Joint Bookrunner
Medtech | July 2021![Iveric Bio CMO](https://stifelinstitutional.com/wp-content/uploads/2021/08/Ivericbio_logo.png)
$ 100,190,000
Joint Bookrunner
Biopharma | July 2021![Cerevel Follow-on](https://stifelinstitutional.com/wp-content/uploads/2021/08/Cerevel_logo.png)
$ 350,000,000
Joint Bookrunner
Biopharma | July 2021![Nyxoah IPO](https://stifelinstitutional.com/wp-content/uploads/2021/08/Nyxoah_logo.png)
$ 97,807,500
Joint Bookrunner
Medtech | July 2021![Vetio Animal – Swedencare M&A](https://stifelinstitutional.com/wp-content/uploads/2021/08/Vetio_Sweden_logo.png)
$ 181,500,000
Advisor to Seller
Biopharma | July 2021![Acumen IPO](https://stifelinstitutional.com/wp-content/uploads/2021/08/Acumen_logo.png)
$ 160,000,000
Joint Bookrunner
Biopharma | June 2021![GH Research IPO](https://stifelinstitutional.com/wp-content/uploads/2021/07/GHResearch_logo.png)
$ 160,000,000
Joint Bookrunner
Biopharma | June 2021![OneSpaWorld Follow-on](https://stifelinstitutional.com/wp-content/uploads/2021/08/OneSpa_logo.png)
$ 80,000,000
Left Bookrunner
Entertainment | June 2021![RCSA M&A](https://stifelinstitutional.com/wp-content/uploads/2021/06/RCSA_Retina_Logo.png)
Advisor to Seller
Healthcare Services | June 2021![Outset Medical – Follow-on Offering](https://stifelinstitutional.com/wp-content/uploads/2021/05/Outset_Logo.png)
$ 366,000,000
Co-Manager
Medtech | April 2021![Evolus 04-2021](https://stifelinstitutional.com/wp-content/uploads/2021/04/Evolus_Logo.png)
$ 98,325,000
Joint Bookrunner
Biopharma | April 2021![SeaSpine Holdings 04-2021](https://stifelinstitutional.com/wp-content/uploads/2021/04/Seaspine_Logo.png)
$ 100,912,500
Joint Bookrunner
Medtech | April 2021![Karuna Therapeutics Follow-on Offering](https://stifelinstitutional.com/wp-content/uploads/2021/05/KarunaTherapeutic_Logos.png)
$ 287,500,000
Joint Bookrunner
Biopharma | April 2021![Maravai Life Sciences 04-2021](https://stifelinstitutional.com/wp-content/uploads/2021/04/Maravai_logo.png)
$ 646,875,000
Joint Bookrunner
Tools & Diagnostics | April 2021![Ionis Pharmaceuticals 04-2021](https://stifelinstitutional.com/wp-content/uploads/2021/01/ionis_logo.png)
$ 550,000,000
Joint Bookrunner
Biopharma | April 2021![ProQR Therapeutics 03-2021](https://stifelinstitutional.com/wp-content/uploads/2021/04/ProQr_Logo.png)
$ 103,500,000
Joint Bookrunner
Biopharma | March 2021![Cti Biopharma 03-2021](https://stifelinstitutional.com/wp-content/uploads/2021/04/Cti-Biopharma_Logo.png)
$ 50,652,000
Left Bookrunner
Biopharma | March 2021![Evofem Biosciences 03-2021](https://stifelinstitutional.com/wp-content/uploads/2021/03/Evofem_logo.png)
$ 30,000,000
Joint Bookrunner
Biopharma | March 2021![AVEO Oncology 03-2021](https://stifelinstitutional.com/wp-content/uploads/2021/03/AVEO-Oncology_logo.png)
$ 48,000,000
Joint Bookrunner
Biopharma | March 2021![PhaseBio Pharmaceuticals 03-2021](https://stifelinstitutional.com/wp-content/uploads/2021/03/PhaseBio_logo.png)
$ 56,000,000
Joint Bookrunner
Biopharma | March 2021![X4 Pharmaceuticals – PIPE](https://stifelinstitutional.com/wp-content/uploads/2021/05/X4_Logo.png)
$ 55,000,000
Joint Placement Agent
Biopharma | March 2021![Prometheus Biosciences 03-2021](https://stifelinstitutional.com/wp-content/uploads/2021/03/Prometheus_Biosciences_logo.png)
$ 218,500,000
Joint Bookrunner
Biopharma | March 2021![Xenon Pharmaceuticals 03-2021](https://stifelinstitutional.com/wp-content/uploads/2021/03/Xenon_logo.png)
$ 115,000,000
Joint Bookrunner
HealthTech | March 2021![Nurix Follow-on Offering](https://stifelinstitutional.com/wp-content/uploads/2021/05/Nurix_Logo.png)
$ 160,425,000
Joint Bookrunner
Biopharma | March 2021![Cutera – Convertible Notes](https://stifelinstitutional.com/wp-content/uploads/2021/05/Cutera_Logo.png)
$ 138,250,000
Sole Bookrunner
Medtech | March 2021![Squadron – Alphatec M&A](https://stifelinstitutional.com/wp-content/uploads/2021/05/Squadron_Alphatec_Logo.png)
$ 90,000,000
Advisor to Squadron
Medtech | March 2021![KalVista 02-2021](https://stifelinstitutional.com/wp-content/uploads/2021/03/KalVista_logo.png)
$ 222,250,000
Joint Bookrunner
HealthTech | February 2021![SQZ Biotechnologies 02-2021](https://stifelinstitutional.com/wp-content/uploads/2021/03/SQZBiotechnologies_logo.png)
$ 60,000,000
Joint Bookrunner
HealthTech | February 2021![Centene – Senior Notes](https://stifelinstitutional.com/wp-content/uploads/2021/05/Centene_Logo.png)
$ 2,200,000,000
Co-Manager
Healthcare Services | February 2021![Rhythm Pharmactuticals 02-2021](https://stifelinstitutional.com/wp-content/uploads/2021/03/RhythmPharmaceuticals_logo.png)
$ 150,000,000
Joint Bookrunner
HealthTech | February 2021![Sientra – Confidentially Marketed Follow-on Offering](https://stifelinstitutional.com/wp-content/uploads/2021/05/Sientra_Logo.png)
$ 42,000,000
Sole Bookrunner
Medtech | February 2021![Bolt Biotherapeutics 02-2021](https://stifelinstitutional.com/wp-content/uploads/2021/02/Bolt-Biotherapeutics_logo.png)
$ 264,500,000
Joint Bookrunner
Biopharma | February 2021![Vor Biopharma 02-2021](https://stifelinstitutional.com/wp-content/uploads/2021/03/VorBiopharma_logo.png)
$ 203,439,942
Joint Bookrunner
Biopharma | February 2021![Angion Biomedica Corp 02-2021](https://stifelinstitutional.com/wp-content/uploads/2021/03/angion_logo.png)
$ 117,000,000
Joint Bookrunner
Biopharma | February 2021![Gemini – SPAC Merger & PIPE](https://stifelinstitutional.com/wp-content/uploads/2021/05/Gemini_Logo.png)
Capital Markets Advisor
Biopharma | February 2021![MaxCyte – PIPE](https://stifelinstitutional.com/wp-content/uploads/2021/05/Maxcyte_Logo.png)
£ 40,000,000
Sole Placement Agent
Biopharma | February 2021![Applied Genetic Technnologies 02-2021](https://stifelinstitutional.com/wp-content/uploads/2021/02/Applied-Genetic-Technnologies_logo.png)
$ 74,500,000
Left Bookrunner
Biopharma | February 2021![DarioHealth Group 02-2021](https://stifelinstitutional.com/wp-content/uploads/2021/02/DarioHealth-Group_logo.png)
$ 70,000,000
Joint Placement Agent
HealthTech | February 2021![Precigen 01-2021](https://stifelinstitutional.com/wp-content/uploads/2021/02/Precigen_logo.png)
$ 129,375,000
Joint Bookrunner
Biopharma | January 2021![Dyne Therapeutics 01-2021](https://stifelinstitutional.com/wp-content/uploads/2021/02/Dyne-Therapeutics_logo.png)
$ 168,000,000
Joint Bookrunner
Biopharma | January 2021![Athira Pharma 01-2021](https://stifelinstitutional.com/wp-content/uploads/2021/02/Athira-Pharma_logo.png)
$ 103,500,000
Joint Bookrunner
Biopharma | January 2021![AdaptHealth Crop 01-2021](https://stifelinstitutional.com/wp-content/uploads/2021/02/adapthealth_logo.png)
$ 264,000,000
Joint Bookrunner
Healthcare Services | January 2021![AbCellera Biologics 12-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/abcellera-biologics_logo.png)
$ 555,450,000
Joint Bookrunner
Biopharma | December 2020![908 Devices 12-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/908-devices_logo.png)
$ 149,500,000
Joint Bookrunner
Tools & Diagnostics | December 2020![IGM Biosciences 12-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/igm-bio_logo.png)
$ 200,000,000
Joint Bookrunner
Biopharma | December 2020![Kura Oncology 12-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/kura-oncology_logo.png)
$ 345,080,500
Joint Bookrunner
Biopharma | December 2020![Repligen 12-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/repligen_logo.png)
$ 312,225,000
Joint Bookrunner
Tools & Diagnostics | December 2020![Codexis 12-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/codexis_logo.png)
$ 750,000,000
Joint Bookrunner
Tools & Diagnostics | December 2020![Silverback Therapeutics 12-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/silverback-therapeutics_logo.png)
$ 277,725,000
Joint Bookrunner
Biopharma | December 2020![Maravai Life Science, Inc. 11-2020](https://stifelinstitutional.com/wp-content/uploads/2021/01/maravai_logo.png)
$ 1,863,000,000
Joint Bookrunner
Tools & Diagnostics | November 2020![SQZ Biotechnologies 11-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/sqz_logo.png)
$ 81,176,464
Joint Bookrunner
Biopharma | November 2020![Lux Health Tech Acquisition Corp. 10-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/luxhealth_logo.png)
$ 345,000,000
Lead Manager
Medtech | October 2020![Eucrates Biomedical 10-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/EuCrates-Biomedical_logo.png)
$ 104,796,260
Left Bookrunner
Medtech | October 2020![Ionis/Akcea 10-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Ionis-Akcea_logo.png)
$ 1,898,938,296
Joint Financial Advisor
Biopharma | October 2020![Pulmonx Corporation 10-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Pulmonx-Corporation_logo.png)
$ 2,128,500,000
Lead Manager
Medtech | October 2020![Zogenix 09-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Zogenix_logo.png)
$ 200,000,000
Joint Bookrunner
Biopharma | September 2020![Athira Pharma 09-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Athira-Pharma_logo.png)
$ 277,761,104
Joint Bookrunner
Biopharma | September 2020![Dyne Therapeutics 09-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Dyne-Therapeutics_logo.png)
$ 267,696,966
Joint Bookrunner
Biopharma | September 2020![Horizon Therapeutics 08-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Horizon-Therapeutics_logo.png)
$ 963,470,000
Joint Bookrunner
Biopharma | August 2020![Elanco/Vetoquinol 08-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Elanco_Vetoquinol_logo.png)
$ 140,000,000
Advisor to Seller
Biopharma | August 2020![Elanco/Vetoquinol 08-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Elanco_Vetoquinol_logo.png)
$ 140,000,000
Advisor to Seller
Biopharma | August 2020![Dechra Pharmaceuticals/Elanco Animal Health Inc. 07-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Dechra-pharmaceuticals_elanco_logo.png)
$ 135,000,000
Advisor to Buyer
Biopharma | July 2020![Cerevel Therapeutics 07-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Cerevel-Therapeutics_logo.png)
$ 445,000,000
Financial Advisor
Biopharma | July 2020![Nurix Therapeutics 07-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Nurix-Therapeutics_logo.png)
$ 209,000,000
Joint Bookrunner
Biopharma | July 2020![Genocea BioSciences 07-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Genocea-BioSciences_logo.png)
$ 80,000,000
Lead Placement Agent
Biopharma | July 2020![Atreca 07-2020](https://stifelinstitutional.com/wp-content/uploads/2021/02/Atreca_logo.png)
$ 120,000,000
Joint Bookrunner
Biopharma | July 2020![Orthopediatrics_Apifix M&A](https://stifelinstitutional.com/wp-content/uploads/2022/04/OrthoPediatrics_ApiFix_Logo.png)
$ 39,054,798
Advisor to Buyer
Medtech | April 2020![Compugen CMO](https://stifelinstitutional.com/wp-content/uploads/2022/05/Compugen_Logo.png)
$ 79,347,051
Joint Bookrunner
Biopharma | March 2020![Moksha8](https://stifelinstitutional.com/wp-content/uploads/2022/10/Moksha8_logo.png)
$ 125,000,000
Financial Advisor
Biopharma | February 2019![Lilly_Uniao Quimica MA](https://stifelinstitutional.com/wp-content/uploads/2022/10/Lilly_UniaoQuimica_logo.png)
Advisor to Seller
Biopharma | September 2018